Wyeth Pharmaceuticals signed a research collaboration with MediVas, LLC, a biomaterials company specializing in improved delivery of biologics. This collaboration was initiated to discover, develop, manufacture and commercialize biopharmaceuticals that extend the duration of action of recombinant factor treatments for hemophilia. MediVas will use a polymer-based drug delivery system to develop advanced delivery methods to create a longer half-life for these proteins. Under the terms of the ...